- Home
- FUTU vs GMAB Comparison
FUTU vs GMAB Comparison
Compare FUTU & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUTU | GMAB |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | Hong Kong | Denmark |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 20.6B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FUTU | GMAB |
|---|---|---|
| Price | $180.22 | $33.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $208.60 | $40.40 |
| AVG Volume (30 Days) | 982.5K | ★ 1.5M |
| Earning Date | 11-18-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 119.17 | ★ 132.41 |
| EPS | 8.95 | ★ 25.10 |
| Revenue | $2,442,834,991.00 | ★ $3,845,670,022.00 |
| Revenue This Year | $85.62 | $24.85 |
| Revenue Next Year | $14.24 | $16.51 |
| P/E Ratio | $20.24 | ★ $1.27 |
| Revenue Growth | ★ 87.15 | 29.57 |
| 52 Week Low | $70.60 | $17.24 |
| 52 Week High | $202.53 | $33.96 |
Technical Indicators
Market Signals| Indicator | FUTU | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 58.42 |
| Support Level | $164.20 | $30.35 |
| Resistance Level | $168.22 | $33.96 |
| Average True Range (ATR) | 4.68 | 0.66 |
| MACD | 2.05 | -0.08 |
| Stochastic Oscillator | 72.53 | 77.15 |
Price Performance
Historical ComparisonAbout FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.